Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
covid-19 vaccine (chadox1-s [recombinant]) (Barinthus Biotherapeutics)
- Development stage
- Discontinued
- Lead developer
- Barinthus Biotherapeutics
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The ChAdOx1-nCoV-19 vaccine (also known as AZD1222, Vaxzevria, or Covishield) is a replication-deficient chimpanzee adenovirus-vectored vaccine developed by the University of Oxford and AstraZeneca to prevent COVID-19 caused by SARS-CoV-2. The vaccine utilizes the ChAdOx1 viral vector to deliver the genetic sequence of the full-length, non-stabilized SARS-CoV-2 spike (S) glycoprotein. Upon intramuscular administration, host cells express the spike protein, which triggers the production of neutralizing antibodies and cellular immune responses against SARS-CoV-2. It was widely authorized and distributed globally during the COVID-19 pandemic, but was voluntarily withdrawn from global markets in May 2024 due to a decline in demand and a surplus of updated variant-specific vaccines.
- Brand names
- CovishieldVaxzevria
- Other names
- AstraZeneca COVID-19 VaccineCOVID-19 Vaccine AstraZenecaCOVID19 Vaccine AstraZenecaCOVID 19 Vaccine AstraZenecaOxford-AstraZeneca COVID-19 vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on covid-19 vaccine (chadox1-s [recombinant]) (Barinthus Biotherapeutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on covid-19 vaccine (chadox1-s [recombinant]) (Barinthus Biotherapeutics).